Contract facts
NONEINGENUITY PATHWAY ANALYSIS MATCH CL LICENSE is a federal NONE award for Fda Office Of Acq Grant Svcs held by Qiagen, LLC. Estimated value $199K ($82K obligated). Current period of performance ends Aug 21, 2025 (potential Aug 21, 2026). Last award drew 2 bidders. Place of performance: JEFFERSON AR. Related solicitation FDA-RFQ-21-1240601.
INGENUITY PATHWAY ANALYSIS MATCH CL LICENSE
Recompete timing
PublicCurrent PoP ended Aug 21, 2025 (365 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Incumbent footprint
Public recordQiagen, LLC — $19.5M obligated across 397 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).
Related awards
Same incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75F40121P00351?
75F40121P00351 (Ingenuity pathway analysis MATCH CL license) is a Fda Office Of Acq Grant Svcs award with a potential value of $199K, currently held by Qiagen, LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75F40121P00351?
Fda Office Of Acq Grant Svcs awarded 75F40121P00351 to Qiagen, LLC (potential $199K).
Who is the incumbent on 75F40121P00351?
Qiagen, LLC is the incumbent with $19.5M across 397 related awards in SCOUT’s public footprint. The current period of performance ends Aug 21, 2025.
When does Qiagen, LLC’s 75F40121P00351 come up for recompete?
SCOUT tracks a period-of-performance end of Aug 21, 2025. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.